Last reviewed · How we verify
NCT06237166: FELYCIA
Evaluation of an Online Intervention for Female Sexual Dysfunction
NA trial testing mylovia in Female Sexual Dysfunction in 252 participants. Completed in 8 May 2025.
10 February 2025
Quick facts
| Lead sponsor | Gaia AG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 252 |
| Start date | 28 May 2024 |
| Primary completion | 10 February 2025 |
| Estimated completion | 8 May 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- mylovia
Conditions studied
- Female Sexual Dysfunction — all drugs for Female Sexual Dysfunction →
Sponsor
Gaia AG — full company profile →
Who can join
18 and older, female only, with Female Sexual Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this randomized controlled clinical trial, 250 participants with female sexual dysfunction will be investigated regarding the effectiveness of an online intervention for improving sexual function, the unguided online intervention mylovia. Inclusion criteria are: female sex and female gender, age ≥18, diagnosed sexual dysfunction (ICD-11: HA00, HA01, HA02) or sexual pain disorder (ICD-11: HA20), low sexual functioning (\<27 on the Female Sexual Function Index; FSFI), sufficient German skills, and consent to participation. Exclusion criteria are: biological, psychological or social factors that might interfere with study participation, and use of another digital intervention for sexual problems. Participants will be randomized and allocated to either an intervention group, receiving access to mylovia in addition to treatment as usual (TAU), or a control group, receiving information material about treatment and counseling options in addition to TAU. Primary endpoint will be sexual functioning assessed via FSFI, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be sexual desire, sexual satisfaction, sexual pain, and general psychopathology.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial.
Blaszcyk W, Büttner M, Betz LT, Riepenhausen A, et al · · 2026 · PMID 41634129 · DOI 10.1038/s41746-026-02385-z
Verify or expand the search:
- PubMed search for NCT06237166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Female Sexual Dysfunction
Currently open trials in the same condition.
- NCT06729151 — Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patient · recruiting
- NCT06116045 — Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder · Phase 2 · recruiting
- NCT06794346 — Sexual Effects of Transdermal or Vaginal Testosterone · Phase 2 · active not recruiting
Other Gaia AG trials
Trials by the same sponsor.
- NCT06529965 — Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM · NA · recruiting
- NCT06601907 — Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder · NA · terminated
- NCT06243978 — Effectiveness of a Digital Health Application for Primary Hypertension (Liebria) · NA · recruiting
- NCT06221930 — Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity D · NA · completed
- NCT06221956 — Effectiveness of a Digital Health Application for Subacute and Chronic Back Pain (Relevis) · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06237166 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gaia AG
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06237166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing